Editas Medicine is a startup based in the United States, most recent round Series-c-plus, 4 tracked investors.
Based in the United States, Editas Medicine is a startup founded in 2013. Its most recent tracked round is Series-c-plus. Brouky records 4 investors associated with the company.
Editas Medicine develops CRISPR-Cas9-based gene editing therapies to treat genetic diseases, including programs targeting Usher syndrome and Duchenne muscular dystrophy.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.